IRLAB Therapeutics AB (publ) (STO: IRLAB.A)
Sweden
· Delayed Price · Currency is SEK 14.40
-0.15 (-1.03%)
Aug 30, 2024, 5:29 PM CET
IRLAB Therapeutics AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 1,027 | 1,188 | 1,168 | 863.2 | 588.4 | 796.3 | Upgrade
|
| Revenue Growth (YoY) | -16.23% | 1.71% | 35.31% | 46.70% | -26.11% | 3.73% | Upgrade
|
| Cost of Revenue | 670 | 791 | 807 | 586.5 | 415.4 | 542.3 | Upgrade
|
| Gross Profit | 357 | 397 | 361 | 276.7 | 173 | 254 | Upgrade
|
| Selling, General & Admin | 285 | 292 | 266 | 189.9 | 149.5 | 179.6 | Upgrade
|
| Research & Development | 24 | 26 | 21 | 16.5 | 15.5 | 12.2 | Upgrade
|
| Other Operating Expenses | -33 | -40 | -27 | -1.8 | -0.2 | -2.9 | Upgrade
|
| Operating Expenses | 276 | 278 | 260 | 204.6 | 164.8 | 188.9 | Upgrade
|
| Operating Income | 81 | 119 | 101 | 72.1 | 8.2 | 65.1 | Upgrade
|
| Interest Expense | -29 | -25 | -12 | -5.6 | -3 | -6.6 | Upgrade
|
| Interest & Investment Income | 2 | 2 | 4 | 1.8 | 2.9 | 8.7 | Upgrade
|
| Earnings From Equity Investments | - | - | - | 0.2 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 2 | 2 | -2 | 12 | -18.4 | -1.7 | Upgrade
|
| Other Non Operating Income (Expenses) | 1 | - | 1 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | 57 | 98 | 92 | 80.5 | -10.3 | 65.5 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -3.5 | - | - | Upgrade
|
| Impairment of Goodwill | -21 | -21 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | -0.5 | Upgrade
|
| Gain (Loss) on Sale of Assets | 1 | 1 | 1 | 0.6 | 8.8 | 8.6 | Upgrade
|
| Pretax Income | 37 | 78 | 93 | 77.6 | -1.5 | 73.6 | Upgrade
|
| Income Tax Expense | 4 | 16 | 22 | 19.5 | -0.9 | 12.2 | Upgrade
|
| Earnings From Continuing Operations | 33 | 62 | 71 | 58.1 | -0.6 | 61.4 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | - | -17.2 | Upgrade
|
| Net Income to Company | 33 | 62 | 71 | 58.1 | -0.6 | 44.2 | Upgrade
|
| Net Income | 33 | 62 | 71 | 58.1 | -0.6 | 44.2 | Upgrade
|
| Net Income to Common | 33 | 62 | 71 | 58.1 | -0.6 | 44.2 | Upgrade
|
| Net Income Growth | -45.00% | -12.68% | 22.20% | - | - | 2226.32% | Upgrade
|
| Shares Outstanding (Basic) | 27 | 27 | 27 | 27 | 27 | 27 | Upgrade
|
| Shares Outstanding (Diluted) | 28 | 28 | 28 | 28 | 27 | 27 | Upgrade
|
| Shares Change (YoY) | 0.13% | - | - | 1.28% | - | 11.47% | Upgrade
|
| EPS (Basic) | 1.21 | 2.27 | 2.60 | 2.13 | -0.02 | 1.66 | Upgrade
|
| EPS (Diluted) | 1.19 | 2.24 | 2.57 | 2.10 | -0.02 | 1.67 | Upgrade
|
| EPS Growth | -45.19% | -12.84% | 22.38% | - | - | - | Upgrade
|
| Free Cash Flow | 68 | 138 | -91 | -9 | 27 | 19.2 | Upgrade
|
| Free Cash Flow Per Share | 2.45 | 4.99 | -3.29 | -0.33 | 0.99 | 0.70 | Upgrade
|
| Dividend Per Share | 0.900 | 0.900 | 0.800 | 0.750 | - | - | Upgrade
|
| Dividend Growth | 12.50% | 12.50% | 6.67% | - | - | - | Upgrade
|
| Gross Margin | 34.76% | 33.42% | 30.91% | 32.06% | 29.40% | 31.90% | Upgrade
|
| Operating Margin | 7.89% | 10.02% | 8.65% | 8.35% | 1.39% | 8.18% | Upgrade
|
| Profit Margin | 3.21% | 5.22% | 6.08% | 6.73% | -0.10% | 5.55% | Upgrade
|
| Free Cash Flow Margin | 6.62% | 11.62% | -7.79% | -1.04% | 4.59% | 2.41% | Upgrade
|
| EBITDA | 159 | 213 | 179 | 103 | 39.4 | 127.3 | Upgrade
|
| EBITDA Margin | 15.48% | 17.93% | 15.33% | 11.93% | 6.70% | 15.99% | Upgrade
|
| D&A For EBITDA | 78 | 94 | 78 | 30.9 | 31.2 | 62.2 | Upgrade
|
| EBIT | 81 | 119 | 101 | 72.1 | 8.2 | 65.1 | Upgrade
|
| EBIT Margin | 7.89% | 10.02% | 8.65% | 8.35% | 1.39% | 8.18% | Upgrade
|
| Effective Tax Rate | 10.81% | 20.51% | 23.66% | 25.13% | - | 16.58% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.